Central Nervous System

Glioma
- Recurrent
- High Grade
  - Pre- Avastin

BRAF Mutation

**BRN0048**
Phase I, First-In-Human, Multi-center, Open-Label Study of ABM-1310, Administered Orally in Adult Patients with Advanced Solid Tumors
PI: Nagpal Sponsor: ABM Therapeutics, Inc.

**BRN0056**
Phase III Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects
PI: Nagpal Sponsor: VBI Vaccines Inc.

**BRN0054**
Phase II Pemigatinib in Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
PI: Lim Sponsor: Incyte Corporation

**BRN0042**
Phase II/III Trial Designed To Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM
PI: Recht Sponsor: Pending

**CCT5061**
Phase I Locoregionally (LP) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme (GBM)
PI: Thomas Sponsor: Stanford University

**BRN0045**
Phase II Exablate Type 2 for BBBD With Microbubble Resonators in TX of rGBM in Carboplatin Mono Treatment
PI: Nagpal Sponsor: InSightec, Inc.

**BRN0049**
Phase Ib Nivolumab or the Combination Nivolumab + Ipilimumab in Surgically Accessible Glioblastoma
PI: Lim Sponsor: Pending

**KEY**
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Trial Posting
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu